SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001178913-22-004019
Filing Date
2022-11-14
Accepted
2022-11-14 16:06:08
Documents
15
Period of Report
2022-11-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8k.htm   iXBRL 8-K 40118
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 16562
7 image0.jpg GRAPHIC 11852
  Complete submission text file 0001178913-22-004019.txt   262690

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cmmb-20221114.xsd EX-101.SCH 4644
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmmb-20221114_def.xml EX-101.DEF 18314
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmmb-20221114_lab.xml EX-101.LAB 28540
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmmb-20221114_pre.xml EX-101.PRE 20556
9 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 6617
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 813676773 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38807 | Film No.: 221385106
SIC: 2834 Pharmaceutical Preparations